Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8001613 | 0.83 | KMT2A (0.43) | KMT2AMAPK1MEN1MAPTOPRM1 | |
| Opaviraline SCHEMBL29388810 | 0.83 | KMT2A (0.43) | KMT2AMAPK1MEN1MAPT | |
| Opaviraline SCHEMBL464732 | 0.83 | KMT2A (0.43) | KMT2AMAPK1MEN1MAPT | |
| Opaviraline SCHEMBL865250 | 0.83 | KMT2A (0.43) | KMT2AMAPK1MEN1MAPT | |
| SCHEMBL4870172 | 0.81 | MAPK1 (0.48) | KMT2AMAPK1MEN1BRD4MAPT | |
| SCHEMBL4916100 | 0.81 | MAPK1 (0.48) | KMT2AMAPK1MEN1BRD4MAPT | |
| SCHEMBL4870381 | 0.81 | MAPK1 (0.48) | KMT2AMAPK1MEN1BRD4MAPT | |
| SCHEMBL4863649 | 0.77 | RAB9A (0.43) | KMT2AMAPK1MAPT | |
| SCHEMBL4869909 | 0.73 | ALDH1A1 (0.42) | KMT2A | |
| SCHEMBL31689283 | 0.72 | KMT2A (0.35) | KMT2AMEN1EGFRNR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | claimed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | claimed |
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | claimed |
| EP-1686113-A1 | Inhibitors of aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1194404-B1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2006-05-03 | — | — | EP | claimed |
| US-6878728-B1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2005-04-12 | — | — | US | claimed |
| US-20040122000-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED. | 2004-06-24 | — | — | US | claimed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7442718-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-28 | — | — | US | disclosed |
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | disclosed |
| CN-101239063-A | Pharmaceutical compositions | GLAXO GROUP LTD (GB) | 2008-08-13 | — | — | CN | disclosed |
| EP-0979082-A1 | ANTIVIRAL COMBINATIONS CONTAINING THE CARBOCYCLIC NUCLEOSIDE 1592U89 | GLAXO GROUP LIMITED (GB) | 2000-02-16 | — | — | EP | disclosed |
| WO-2000004033-A1 | CALCIUM (3S) TETRAHYDRO-3-FURANYL(1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO] -1-BENZYL-2- (PHOSPHONOOXY) PROPYLCARBAMATE | GLAXO GROUP LIMITED (GB) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999064001-A2 | METHODS AND COMPOSITIONS FOR INCREASING PENETRATION OF HIV PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999055372-A1 | HOMOGENEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING ABACAVIR, LAMIVUDINE AND ZIDOVUDINE | GLAXO GROUP LIMITED (GB) | 1999-11-04 | — | — | WO | disclosed |
| WO-1999039691-A2 | PHARMACEUTICAL COMPOSITIONS | GLAXO GROUP LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
| WO-1998056761-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-12-17 | — | — | WO | disclosed |
| WO-1998052570-A1 | ANTIVIRAL COMBINATIONS CONTAINING THE CARBOCYCLIC NUCLEOSIDE 1592U89 | GLAXO GROUP LIMITED (GB) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042973-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | KMT2A 864/4885MAPK1 3466/4885MEN1 4418/4885 |
| US-20040122000-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | KMT2A 864/4885MAPK1 3466/4885MEN1 4418/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | KMT2A 864/4885MAPK1 3466/4885MEN1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.